<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8401784</journal-id>
<journal-id journal-id-type="pubmed-jr-id">99</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Dev Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int. J. Dev. Neurosci.</journal-id>
<journal-title-group>
<journal-title>International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0736-5748</issn>
<issn pub-type="epub">1873-474X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30385191</article-id>
<article-id pub-id-type="pmc">6354926</article-id>
<article-id pub-id-type="doi">10.1016/j.ijdevneu.2018.10.002</article-id>
<article-id pub-id-type="manuscript">NIHMS1513090</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Increased Severity of Fragile X Spectrum Disorders in the Agricultural Community of Ricaurte, Colombia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Saldarriaga</surname>
<given-names>Wilmar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>María J</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Guerrero</surname>
<given-names>Tatiana</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ríos</surname>
<given-names>Marcela</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fandiño-Losada</surname>
<given-names>Andrés</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramirez-Cheyne</surname>
<given-names>Julian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lein</surname>
<given-names>Pamela J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>School of Medicine, Universidad del Valle, Cali, Colombia</aff>
<aff id="A2"><label>2</label>Research Group in Congenital &amp; Perinatal Malformations, Dysmorphology and Clinical Genetics (MACOS), Universidad del Valle, Cali, Colombia</aff>
<aff id="A3"><label>3</label>Department of Morphology, Universidad del Valle, Cali, Colombia</aff>
<aff id="A4"><label>4</label>Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, USA</aff>
<aff id="A5"><label>5</label>CISALVA Institute, School of Public Health, Faculty of Health, Universidad del Valle, Cali, Colombia</aff>
<aff id="A6"><label>6</label>Department of Molecular Biosciences, University of California Davis School of Veterinary Medicine, Davis, CA, USA</aff>
<aff id="A7"><label>7</label>Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA, USA</aff>
<aff id="A8"><label>8</label>Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA</aff>
<author-notes>
<corresp id="CR1"><bold>Corresponding author:</bold> Randi Hagerman, MD, MIND Institute UCDMC, 2825 50<sup>th</sup> Street, Sacramento, California, 95817, <email>rjhagerman@ucdmc.edu</email>, Maria J Salcedo-Arellano, MD, MIND Institute UCDMC, 2825 50<sup>th</sup> Street, Sacramento, California, 95817, <email>mjsalcedo@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P23"><bold>Disclosure statement:</bold> RH has received funding from Roche, Novartis, Neuren, Marinus and Alcobra for carrying out treatment studies in patients with fragile X syndrome. She has also consulted with Fulcrum, Ovid and Zynerba regarding treatment studies in individuals with fragile X syndrome. The other authors declare no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>72</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<!--elocation-id from pubmed: 10.1016/j.ijdevneu.2018.10.002-->
<abstract id="ABS1">
<p id="P1">Premutation carriers of the <italic>FMR1</italic> gene (CGG repeats between 55 and 200) usually have normal intellectual abilities but approximately 20% are diagnosed with developmental problems or autism spectrum disorder. Additionally, close to 50% have psychiatric problems such as anxiety, ADHD and/or depression. The spectrum of fragile X disorders also includes Fragile-X-associated primary ovarian insufficiency (FXPOI) in female carriers and Fragile-X-associated tremor/ataxia syndrome (FXTAS) in older male and female carriers.</p>
<p id="P2">We evaluated 25 premutation carriers in the rural community of Ricaurte Colombia and documented all behavioral problems, social deficits and clinical signs of FXPOI and FXTAS as well as reviewed the medical and obstetric history.</p>
<p id="P3">We found an increased frequency and severity of symptoms of fragile X spectrum disorders, which might be related to the vulnerability of <italic>FMR1</italic> premutation carriers to higher exposure to neurotoxic pesticides in this rural community.</p>
</abstract>
<kwd-group>
<kwd>Fragile X syndrome</kwd>
<kwd>fragile X spectrum disorders</kwd>
<kwd>FXTAS</kwd>
<kwd>FXPOI</kwd>
<kwd>Colombia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>